Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewGuanabenz acetate
Discontinued Product
0885 has been discontinued.
View all Adrenergic α<sub>2</sub> Receptors products.
Description: α2 agonist. Also I2 selective ligand
Chemical Name: [(2,6-Dichlorobenzylidene)amino]guanidine acetate
Purity: ≥98% (HPLC)
Biological Activity for Guanabenz acetate
Guanabenz acetate is a α2-adrenergic agonist and IGRS (imidazoline I2 binding site) selective ligand.
Technical Data for Guanabenz acetate
| M. Wt | 291.14 |
| Formula | C8H8Cl2N4.CH3CO2H |
| Storage | Store at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 23256-50-0 |
| PubChem ID | 5702062 |
| InChI Key | MCSPBPXATWBACD-GAYQJXMFSA-N |
| Smiles | CC(O)=O.ClC1=C(/C=N/NC(N)=N)C(Cl)=CC=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Guanabenz acetate
References for Guanabenz acetate
References are publications that support the biological activity of the product.
Evans and Anderson (1995) Renal effects of infusion of rilmenidine and guan. in conscious dogs: contribution of peripheral and central nervous system α2-adrenoceptors. Br.J.Pharmacol. 116 1557 PMID: 8564219
Holmes et al (1983) Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 26 212 PMID: 6352237
Michel and Insel (1989) Are there multiple imidazoline binding sites? Trends Pharmacol.Sci. 10 342 PMID: 2690423
Merck Index 12 4585
View Related Products by Target
View Related Products by Product Action
Keywords: Guanabenz acetate, Guanabenz acetate supplier, α2-adrenoceptor, alpha2-adrenoceptor, α2-Adrenergic, alpha2-Adrenergic, a2-adrenoceptor, a2-adrenergic, agonists, I2, selective, ligands, Adrenoceptors, Imidazoline, Adrenergic, Alpha-2, Receptors, 0885, Tocris Bioscience
5 Citations for Guanabenz acetate
Citations are publications that use Tocris products. Selected citations for Guanabenz acetate include:
Nevin et al (2017) Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes. Am J Hum Genet 100 617 PMID: 28366443
Wan et al (2014) Distinctive subcellular inhibition of cytokine-induced SRC by salubrinal and fluid flow. PLoS One 9 e105699 PMID: 25157407
Hamamura et al (2015) Chondroprotective effects of Salubrinal in a mouse model of osteoarthritis. Proc Natl Acad Sci U S A 4 84 PMID: 25977571
Ye et al (2013) Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. J Korean Med Sci 110 141 PMID: 23248313
Cardin and Schmidt (2004) Noradrenergic inputs mediate state dependence of auditory responses in the avian song system. Bone Joint Res 24 7745 PMID: 15342742
Reviews for Guanabenz acetate
There are currently no reviews for this product. Be the first to review Guanabenz acetate and earn rewards!
Have you used Guanabenz acetate?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.